Jilin Aodong Pharmaceutical Group Co., Ltd. Jilin Aodong Pharmaceutical Group Co., Ltd.

Jilin Aodong Pharmaceutical Group Co., Ltd.

000623

株式のランク #4951
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
株価
$2.47
時価総額
$2.95B
変化(1日)
0.00%
変化(1年)
-14.68%
国
CN
取引 Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)

カテゴリー

Healthcare
Jilin Aodong Pharmaceutical Group Co., Ltd.(000623)の利益
Jun 2026 時点の利益 TTM: $450.70M
Jilin Aodong Pharmaceutical Group Co., Ltd. の最新の財務報告によると、同社の現在の利益は $450.70M です。2023 年には $211.93M の利益を上げ、これは 2022 年の利益 $249.47M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Jilin Aodong Pharmaceutical Group Co., Ltd. の利益の推移(2000 〜 2026)
各年末の利益
年 利益 変化
2026 (TTM) $450.70M 116.23%
2024 $208.44M -1.65%
2023 $211.93M -15.05%
2022 $249.47M -10.25%
2021 $277.96M 5.78%
2020 $262.76M 23.65%
2019 $212.51M 47.80%
2018 $143.78M -51.61%
2017 $297.11M 18.54%
2016 $250.63M -39.05%
2015 $411.21M 71.49%
2014 $239.79M 22.14%
2013 $196.32M 79.35%
2012 $109.46M -71.97%
2011 $390.52M 99.92%
2010 $195.34M -5.51%
2009 $206.72M 55.20%
2008 $133.20M -52.18%
2007 $278.56M 315.81%
2006 $66.99M 289.48%
2005 $17.20M -21.22%
2004 $21.83M 20.73%
2003 $18.09M 43.68%
2002 $12.59M 67.81%
2001 $7.50M -36.78%
2000 $11.87M 0.00%